399 related articles for article (PubMed ID: 17264186)
1. Adiponectin levels in prepubertal children with Prader-Willi syndrome before and during growth hormone therapy.
Festen DA; van Toorenenbergen A; Duivenvoorden HJ; Hokken-Koelega AC
J Clin Endocrinol Metab; 2007 Apr; 92(4):1549-54. PubMed ID: 17264186
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular and metabolic risk profile and acylation-stimulating protein levels in children with Prader-Willi syndrome and effects of growth hormone treatment.
de Lind van Wijngaarden RF; Cianflone K; Gao Y; Leunissen RW; Hokken-Koelega AC
J Clin Endocrinol Metab; 2010 Apr; 95(4):1758-66. PubMed ID: 20173020
[TBL] [Abstract][Full Text] [Related]
3. Dietary Energy Intake, Body Composition and Resting Energy Expenditure in Prepubertal Children with Prader-Willi Syndrome before and during Growth Hormone Treatment: A Randomized Controlled Trial.
Bakker NE; Siemensma EP; Koopman C; Hokken-Koelega AC
Horm Res Paediatr; 2015; 83(5):321-31. PubMed ID: 25764996
[TBL] [Abstract][Full Text] [Related]
4. Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome.
Festen DA; de Lind van Wijngaarden R; van Eekelen M; Otten BJ; Wit JM; Duivenvoorden HJ; Hokken-Koelega AC
Clin Endocrinol (Oxf); 2008 Sep; 69(3):443-51. PubMed ID: 18363884
[TBL] [Abstract][Full Text] [Related]
5. Correlation of adiponectin receptor expression with cytokines and insulin sensitivity in growth hormone (GH)-treated children with Prader-Willi syndrome and in non-GH-treated obese children.
Sohn YB; Kwak MJ; Kim SJ; Park SW; Kim CH; Kim MY; Kwon EK; Paik KH; Jin DK
J Clin Endocrinol Metab; 2010 Mar; 95(3):1371-7. PubMed ID: 20061428
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory markers in adults with Prader-Willi syndrome before and during 12 months growth hormone treatment.
Höybye C
Horm Res; 2006; 66(1):27-32. PubMed ID: 16685133
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of long-term continuous growth hormone treatment in children with Prader-Willi syndrome.
de Lind van Wijngaarden RF; Siemensma EP; Festen DA; Otten BJ; van Mil EG; Rotteveel J; Odink RJ; Bindels-de Heus GC; van Leeuwen M; Haring DA; Bocca G; Houdijk EC; Hoorweg-Nijman JJ; Vreuls RC; Jira PE; van Trotsenburg AS; Bakker B; Schroor EJ; Pilon JW; Wit JM; Drop SL; Hokken-Koelega AC
J Clin Endocrinol Metab; 2009 Nov; 94(11):4205-15. PubMed ID: 19837938
[TBL] [Abstract][Full Text] [Related]
8. Effects of growth hormone therapy on glucose metabolism and insulin sensitivity indices in prepubertal children with Prader-Willi syndrome.
Crinò A; Di Giorgio G; Manco M; Grugni G; Maggioni A
Horm Res; 2007; 68(2):83-90. PubMed ID: 17337902
[TBL] [Abstract][Full Text] [Related]
9. Growth hormone treatment of adults with Prader-Willi syndrome and growth hormone deficiency improves lean body mass, fractional body fat, and serum triiodothyronine without glucose impairment: results from the United States multicenter trial.
Mogul HR; Lee PD; Whitman BY; Zipf WB; Frey M; Myers S; Cahan M; Pinyerd B; Southren AL
J Clin Endocrinol Metab; 2008 Apr; 93(4):1238-45. PubMed ID: 18211968
[TBL] [Abstract][Full Text] [Related]
10. Growth hormone treatment of children with Prader-Willi syndrome: effects on glucose and insulin homeostasis. Swedish National Growth Hormone Advisory Group.
Lindgren AC; Hagenäs L; Ritzén EM
Horm Res; 1999; 51(4):157-61. PubMed ID: 10474015
[TBL] [Abstract][Full Text] [Related]
11. Sleep-related breathing disorders in prepubertal children with Prader-Willi syndrome and effects of growth hormone treatment.
Festen DA; de Weerd AW; van den Bossche RA; Joosten K; Hoeve H; Hokken-Koelega AC
J Clin Endocrinol Metab; 2006 Dec; 91(12):4911-5. PubMed ID: 17003096
[TBL] [Abstract][Full Text] [Related]
12. Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome.
Myers SE; Carrel AL; Whitman BY; Allen DB
J Pediatr; 2000 Jul; 137(1):42-9. PubMed ID: 10891820
[TBL] [Abstract][Full Text] [Related]
13. Bone mineral density in children and adolescents with Prader-Willi syndrome: a longitudinal study during puberty and 9 years of growth hormone treatment.
Bakker NE; Kuppens RJ; Siemensma EP; Tummers-de Lind van Wijngaarden RF; Festen DA; Bindels-de Heus GC; Bocca G; Haring DA; Hoorweg-Nijman JJ; Houdijk EC; Jira PE; Lunshof L; Odink RJ; Oostdijk W; Rotteveel J; Van Alfen AA; Van Leeuwen M; Van Wieringen H; Wegdam-den Boer ME; Zwaveling-Soonawala N; Hokken-Koelega AC
J Clin Endocrinol Metab; 2015 Apr; 100(4):1609-18. PubMed ID: 25668198
[TBL] [Abstract][Full Text] [Related]
14. The effect of growth hormone on the response of total and acylated ghrelin to a standardized oral glucose load and insulin resistance in children with Prader-Willi syndrome.
Hauffa BP; Haase K; Range IM; Unger N; Mann K; Petersenn S
J Clin Endocrinol Metab; 2007 Mar; 92(3):834-40. PubMed ID: 17192298
[TBL] [Abstract][Full Text] [Related]
15. Carbohydrate metabolism is not impaired after 3 years of growth hormone therapy in children with Prader-Willi syndrome.
L'Allemand D; Eiholzer U; Schlumpf M; Torresani T; Girard J
Horm Res; 2003; 59(5):239-48. PubMed ID: 12714788
[TBL] [Abstract][Full Text] [Related]
16. IGF-1 Levels, Complex Formation, and IGF Bioactivity in Growth Hormone-Treated Children With Prader-Willi Syndrome.
Bakker NE; van Doorn J; Renes JS; Donker GH; Hokken-Koelega AC
J Clin Endocrinol Metab; 2015 Aug; 100(8):3041-9. PubMed ID: 26050733
[TBL] [Abstract][Full Text] [Related]
17. Randomized controlled trial to investigate the effects of growth hormone treatment on scoliosis in children with Prader-Willi syndrome.
de Lind van Wijngaarden RF; de Klerk LW; Festen DA; Duivenvoorden HJ; Otten BJ; Hokken-Koelega AC
J Clin Endocrinol Metab; 2009 Apr; 94(4):1274-80. PubMed ID: 19158197
[TBL] [Abstract][Full Text] [Related]
18. One year of growth hormone treatment in adults with Prader-Willi syndrome improves body composition: results from a randomized, placebo-controlled study.
Sode-Carlsen R; Farholt S; Rabben KF; Bollerslev J; Schreiner T; Jurik AG; Christiansen JS; Höybye C
J Clin Endocrinol Metab; 2010 Nov; 95(11):4943-50. PubMed ID: 20702523
[TBL] [Abstract][Full Text] [Related]
19. Bone mineral density and effects of growth hormone treatment in prepubertal children with Prader-Willi syndrome: a randomized controlled trial.
de Lind van Wijngaarden RF; Festen DA; Otten BJ; van Mil EG; Rotteveel J; Odink RJ; van Leeuwen M; Haring DA; Bocca G; Mieke Houdijk EC; Hokken-Koelega AC
J Clin Endocrinol Metab; 2009 Oct; 94(10):3763-71. PubMed ID: 19622627
[TBL] [Abstract][Full Text] [Related]
20. Growth hormone therapy for children and adolescents with Prader-Willi syndrome is associated with improved body composition and metabolic status in adulthood.
Coupaye M; Lorenzini F; Lloret-Linares C; Molinas C; Pinto G; Diene G; Mimoun E; Demeer G; Labrousse F; Jauregi J; Laurier V; Basdevant A; Polak M; Thuilleaux D; Tauber M; Poitou C
J Clin Endocrinol Metab; 2013 Feb; 98(2):E328-35. PubMed ID: 23284006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
